Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

BACKGROUND: The survival outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable. This study investigated whether pre‐ and on‐treatment lactate dehydrogenase (LDH) could better prognosticate and select patients for ICI thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjokrowidjaja, Angelina, Lord, Sarah J., John, Thomas, Lewis, Craig R., Kok, Peey‐Sei, Marschner, Ian C., Lee, Chee K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306897/
https://www.ncbi.nlm.nih.gov/pubmed/35090047
http://dx.doi.org/10.1002/cncr.34113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306897/
https://www.ncbi.nlm.nih.gov/pubmed/35090047
http://dx.doi.org/10.1002/cncr.34113

Ejemplares similares